PT - JOURNAL ARTICLE AU - Chen, Xinhua AU - Wang, Wei AU - Chen, Xinghui AU - Wu, Qianhui AU - Sun, Ruijia AU - Ge, Shijia AU - Zheng, Nan AU - Lu, Wanying AU - Yang, Juan AU - Rodewald, Lance AU - Yu, Hongjie TI - Prediction of long-term kinetics of vaccine-elicited neutralizing antibody and time-varying vaccine-specific efficacy against the SARS-CoV-2 Delta variant by clinical endpoint AID - 10.1101/2021.09.23.21263715 DP - 2021 Jan 01 TA - medRxiv PG - 2021.09.23.21263715 4099 - http://medrxiv.org/content/early/2021/09/27/2021.09.23.21263715.short 4100 - http://medrxiv.org/content/early/2021/09/27/2021.09.23.21263715.full AB - Evidence on vaccine-specific protection over time and boosting impact against the Delta variant across different clinical endpoints and age groups is urgently needed. To address this, we used a previously published model, combined with neutralization data for four vaccines - mRNA-1273, BNT162b2, NVX-CoV2373, and CoronaVac - to evaluate long-term dynamics of neutralizing antibody and to predict time-varying efficacy against the Delta variant by specific vaccine, age group, and clinical severity. We found that booster vaccination produces higher neutralization titers compared with titers observed following primary-series vaccination for all vaccines studied. We estimate the efficacies of mRNA-1273 and BNT162b2 against Delta variant infection to be 63.5% (95%CI: 51.4-67.3%) and 78.4% (95%CI: 72.2-83.5%), respectively, 14-30 days after the second dose, and that efficacies decreased to 36.0% (95%CI: 24.1-58.0%) and 38.5% (95%CI: 28.7-49.1%) 6-8 months later. After administration of booster doses, efficacies against the Delta variant would be 97.0% (95%CI: 96.4-98.5%) and 97.2% (95.7-98.1%). All four vaccines are predicted to provide good protection against severe illness from the Delta variant after both primary and booster vaccination. Long-term monitoring and surveillance of antibody dynamics and vaccine protection, as well as further validation of neutralizing antibody or other markers that can serve as correlates of protection against SARS-CoV-2 and its variants are needed to inform COVID-19 pandemic preparedness.Competing Interest StatementH.Y. has received research funding from Sanofi Pasteur, and Shanghai Roche Pharmaceutical Company; None of those research funding is related to COVID-19. All other authors report no competing interests.Funding StatementThis study was funded by the Key Program of the National Natural Science Foundation of China (82130093).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All data used in this paper were in the public domain. Ethics committees of School of public health, Fudan university states that ethnical approval of re-use of these secondary data is not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from the corresponding author by email.